Praxis Precision Medicines, Inc. (PRAX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Boston, MA, United States. Der aktuelle CEO ist Marcio Silva De'Souza.
PRAX hat IPO-Datum 2020-10-16, 116 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $7.26B.
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders caused by neuronal imbalance. The company's lead candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor modulator in Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel inhibitor in Phase IIa development for essential tremor. Praxis is also advancing PRAX-562 for severe pediatric epilepsy and adult headache disorders, along with antisense oligonucleotide programs PRAX-222 and KCNT1 targeting genetic forms of epilepsy. Founded in 2015 and headquartered in Boston, Massachusetts, the company has established partnerships with RogCon Inc., Purdue Neuroscience Company, Ionis Pharmaceuticals, and The Florey Institute to support its clinical pipeline.
